BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants May 26, 2023 11:25am EDT
BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants May 24, 2023 9:14am EDT
BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023 May 11, 2023 4:21pm EDT
BIOLASE DELIVERS 24% REVENUE GROWTH IN 2022 AS GO-TO-MARKET STRATEGIES GAIN MOMENTUM; GUIDES FOR AT LEAST 25% REVENUE GROWTH AND PROFITABILITY IN 2023 Mar 28, 2023 4:05pm EDT
BIOLASE GATHERS KEY OPINION LEADERS AND DENTAL CLINICIANS TO HIGHLIGHT TONGUE-TIE TREATMENT BEST PRACTICES Mar 14, 2023 6:30am EDT
BIOLASE TO REPORT FOURTH QUARTER AND FULL YEAR 2022 RESULTS ON MARCH 28, 2023 Mar 13, 2023 6:30am EDT
BIOLASE LAUNCHES E-COMMERCE SITE TO ENHANCE POSITIVE USER EXPERIENCE AND STREAMLINE THE PURCHASING PROCESS TO CREATE GREATER EFFICIENCIES FOR DENTAL PRACTITIONERS Feb 27, 2023 6:30am EST
BIOLASE ENTERS THE SKIN RESURFACING MARKET IN THE U.S. WITH THE LAUNCH OF A NEW WATERLASE FRACTIONAL HANDPIECE Feb 23, 2023 6:30am EST
